Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amarnath Sharma

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|March 18, 2018
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasisChuanpu Hu, Zhenling Yao, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 18, 2017
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's diseaseChuanpu Hu, Omoniyi J Adedokun, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 2, 2018
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumabChuanpu Hu, Yan Xu, Yanli Zhuang, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque PsoriasisWangda Zhou, Chuanpu Hu, Yaowei Zhu, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2007
Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjectsPing Liu, Grover Foster, Kuan Gandelman, et al.
Journal of Clinical Pharmacology|February 7, 2020
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative ColitisYan Xu, Chuanpu Hu, Yang Chen, et al.
Innovations in Clinical Neuroscience|August 24, 2011
How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case StudyJoan Shen, Sheldon Preskorn, Vladimir Dragalin, et al.
Clinical and Translational Science|December 2, 2021
Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritisYang Chen, Xin Miao, Chyi-Hung Hsu, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2007
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safetyFeng Guo, Stephen P Letrent, Pamela N Munster, et al.
Journal of Clinical Pharmacology|January 18, 2018
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque PsoriasisZhenling Yao, Chuanpu Hu, Yaowei Zhu, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Journal of Pharmacokinetics and Pharmacodynamics|March 18, 2018
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasisChuanpu Hu, Zhenling Yao, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 18, 2017
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's diseaseChuanpu Hu, Omoniyi J Adedokun, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 2, 2018
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumabChuanpu Hu, Yan Xu, Yanli Zhuang, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque PsoriasisWangda Zhou, Chuanpu Hu, Yaowei Zhu, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2007
Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjectsPing Liu, Grover Foster, Kuan Gandelman, et al.
Journal of Clinical Pharmacology|February 7, 2020
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative ColitisYan Xu, Chuanpu Hu, Yang Chen, et al.
Innovations in Clinical Neuroscience|August 24, 2011
How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case StudyJoan Shen, Sheldon Preskorn, Vladimir Dragalin, et al.
Clinical and Translational Science|December 2, 2021
Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritisYang Chen, Xin Miao, Chyi-Hung Hsu, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2007
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safetyFeng Guo, Stephen P Letrent, Pamela N Munster, et al.
Journal of Clinical Pharmacology|January 18, 2018
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque PsoriasisZhenling Yao, Chuanpu Hu, Yaowei Zhu, et al.
Pageof 5